Which has preferable valuation and earnings, PDEX or LUNG?

Pro-Dex has higher earnings, but lower revenue than Pulmonx. Pulmonx is trading at a lower price-to-earnings ratio than Pro-Dex, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Pro-Dex $66.59M 3.04 $8.98M $3.62 17.51 Pulmonx $90.50M 0.60 -$54M -$1.30 N/A

Is PDEX or LUNG more profitable?

Pro-Dex has a net margin of 16.08% compared to Pulmonx's net margin of -60.09%. Pro-Dex's return on equity of 22.78% beat Pulmonx's return on equity. Company Net Margins Return on Equity Return on Assets Pro-Dex 16.08% 22.78% 14.30% Pulmonx -60.09% -92.94% -39.80%

Does the media favor PDEX or LUNG?

In the previous week, Pro-Dex and Pro-Dex both had 2 articles in the media. Pro-Dex's average media sentiment score of 0.00 equaled Pulmonx'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pro-Dex 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Pulmonx 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is APYX or LUNG more profitable?

Apyx Medical has a net margin of -16.40% compared to Pulmonx's net margin of -60.09%. Apyx Medical's return on equity of -88.47% beat Pulmonx's return on equity. Company Net Margins Return on Equity Return on Assets Apyx Medical -16.40% -88.47% -14.94% Pulmonx -60.09% -92.94% -39.80%

Does the media prefer APYX or LUNG?

In the previous week, Apyx Medical had 2 more articles in the media than Pulmonx. MarketBeat recorded 4 mentions for Apyx Medical and 2 mentions for Pulmonx. Apyx Medical's average media sentiment score of 1.05 beat Pulmonx's score of 0.00 indicating that Apyx Medical is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Apyx Medical 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Pulmonx 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is LUCD or LUNG more profitable?

Pulmonx has a net margin of -60.09% compared to Lucid Diagnostics' net margin of -876.72%. Lucid Diagnostics' return on equity of 0.00% beat Pulmonx's return on equity. Company Net Margins Return on Equity Return on Assets Lucid Diagnostics -876.72% N/A -116.26% Pulmonx -60.09% -92.94% -39.80%

Which has better earnings & valuation, RXST or LUNG?

RxSight has higher revenue and earnings than Pulmonx. RxSight is trading at a lower price-to-earnings ratio than Pulmonx, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio RxSight $127.48M 1.70 -$38.94M -$1.13 N/A Pulmonx $90.50M 0.60 -$54M -$1.30 N/A

Is RXST or LUNG more profitable?

RxSight has a net margin of -36.58% compared to Pulmonx's net margin of -60.09%. RxSight's return on equity of -17.01% beat Pulmonx's return on equity. Company Net Margins Return on Equity Return on Assets RxSight -36.58% -17.01% -15.12% Pulmonx -60.09% -92.94% -39.80%

Does the media favor RXST or LUNG?

In the previous week, Pulmonx had 1 more articles in the media than RxSight. MarketBeat recorded 2 mentions for Pulmonx and 1 mentions for RxSight. RxSight's average media sentiment score of 0.00 equaled Pulmonx'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment RxSight 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Pulmonx 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher valuation & earnings, SMTI or LUNG?

Sanara MedTech has higher revenue and earnings than Pulmonx. Sanara MedTech is trading at a lower price-to-earnings ratio than Pulmonx, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Sanara MedTech $103.12M 1.93 -$37.56M -$3.77 N/A Pulmonx $90.50M 0.60 -$54M -$1.30 N/A

Is SMTI or LUNG more profitable?

Sanara MedTech has a net margin of -31.23% compared to Pulmonx's net margin of -60.09%. Sanara MedTech's return on equity of -3.19% beat Pulmonx's return on equity. Company Net Margins Return on Equity Return on Assets Sanara MedTech -31.23% -3.19% -0.56% Pulmonx -60.09% -92.94% -39.80%

Does the media prefer SMTI or LUNG?

In the previous week, Sanara MedTech and Sanara MedTech both had 2 articles in the media. Sanara MedTech's average media sentiment score of 1.78 beat Pulmonx's score of 0.00 indicating that Sanara MedTech is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sanara MedTech 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Pulmonx 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Pulmonx (LUNG) Competitors

$1.28 +0.01 (+0.79%)

Closing price 06/23/2026 04:00 PM Eastern

Extended Trading

$1.26 -0.02 (-1.48%)

As of 07:59 AM Eastern

Compare

LUNG vs. PDEX, APYX, LUCD, RXST, and SMTI

Should you buy Pulmonx stock or one of its competitors? MarketBeat compares Pulmonx with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Pulmonx include Pro-Dex (PDEX), Apyx Medical (APYX), Lucid Diagnostics (LUCD), RxSight (RXST), and Sanara MedTech (SMTI). These companies are all part of the "medical equipment" industry.

How does Pulmonx compare to Pro-Dex?

Pro-Dex (NASDAQ:PDEX) and Pulmonx (NASDAQ:LUNG) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, earnings, risk, analyst recommendations, institutional ownership, dividends, media sentiment and valuation.

15.3% of Pro-Dex shares are held by institutional investors. Comparatively, 91.0% of Pulmonx shares are held by institutional investors. 45.9% of Pro-Dex shares are held by insiders. Comparatively, 6.8% of Pulmonx shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Pro-Dex has a net margin of 16.08% compared to Pulmonx's net margin of -60.09%. Pro-Dex's return on equity of 22.78% beat Pulmonx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pro-Dex	16.08%	22.78%	14.30%
Pulmonx	-60.09%	-92.94%	-39.80%

Pro-Dex has a beta of -0.02, indicating that its stock price is 102% less volatile than the broader market. Comparatively, Pulmonx has a beta of 0.28, indicating that its stock price is 72% less volatile than the broader market.

In the previous week, Pro-Dex and Pro-Dex both had 2 articles in the media. Pro-Dex's average media sentiment score of 0.00 equaled Pulmonx'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pro-Dex	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Pulmonx	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Pro-Dex presently has a consensus target price of $70.00, indicating a potential upside of 10.43%. Pulmonx has a consensus target price of $5.58, indicating a potential upside of 336.20%. Given Pulmonx's stronger consensus rating and higher possible upside, analysts clearly believe Pulmonx is more favorable than Pro-Dex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pro-Dex	0 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.33
Pulmonx	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

Pro-Dex has higher earnings, but lower revenue than Pulmonx. Pulmonx is trading at a lower price-to-earnings ratio than Pro-Dex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pro-Dex	$66.59M	3.04	$8.98M	$3.62	17.51
Pulmonx	$90.50M	0.60	-$54M	-$1.30	N/A

Summary

Pro-Dex beats Pulmonx on 8 of the 14 factors compared between the two stocks.

How does Pulmonx compare to Apyx Medical?

Apyx Medical (NASDAQ:APYX) and Pulmonx (NASDAQ:LUNG) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their media sentiment, earnings, analyst recommendations, dividends, risk, institutional ownership, profitability and valuation.

Apyx Medical has a net margin of -16.40% compared to Pulmonx's net margin of -60.09%. Apyx Medical's return on equity of -88.47% beat Pulmonx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Apyx Medical	-16.40%	-88.47%	-14.94%
Pulmonx	-60.09%	-92.94%	-39.80%

55.3% of Apyx Medical shares are owned by institutional investors. Comparatively, 91.0% of Pulmonx shares are owned by institutional investors. 15.2% of Apyx Medical shares are owned by company insiders. Comparatively, 6.8% of Pulmonx shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Apyx Medical currently has a consensus price target of $6.50, indicating a potential upside of 59.31%. Pulmonx has a consensus price target of $5.58, indicating a potential upside of 336.20%. Given Pulmonx's higher probable upside, analysts clearly believe Pulmonx is more favorable than Apyx Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Apyx Medical	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67
Pulmonx	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

In the previous week, Apyx Medical had 2 more articles in the media than Pulmonx. MarketBeat recorded 4 mentions for Apyx Medical and 2 mentions for Pulmonx. Apyx Medical's average media sentiment score of 1.05 beat Pulmonx's score of 0.00 indicating that Apyx Medical is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Apyx Medical	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Pulmonx	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Apyx Medical has a beta of 1.39, meaning that its stock price is 39% more volatile than the broader market. Comparatively, Pulmonx has a beta of 0.28, meaning that its stock price is 72% less volatile than the broader market.

Apyx Medical has higher earnings, but lower revenue than Pulmonx. Apyx Medical is trading at a lower price-to-earnings ratio than Pulmonx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Apyx Medical	$55.90M	3.06	-$11.21M	-$0.22	N/A
Pulmonx	$90.50M	0.60	-$54M	-$1.30	N/A

Summary

Apyx Medical beats Pulmonx on 12 of the 17 factors compared between the two stocks.

How does Pulmonx compare to Lucid Diagnostics?

Lucid Diagnostics (NASDAQ:LUCD) and Pulmonx (NASDAQ:LUNG) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, risk, dividends, valuation, earnings, media sentiment, institutional ownership and profitability.

Pulmonx has a net margin of -60.09% compared to Lucid Diagnostics' net margin of -876.72%. Lucid Diagnostics' return on equity of 0.00% beat Pulmonx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lucid Diagnostics	-876.72%	N/A	-116.26%
Pulmonx	-60.09%	-92.94%	-39.80%

Lucid Diagnostics has a beta of 1.08, indicating that its stock price is 8% more volatile than the broader market. Comparatively, Pulmonx has a beta of 0.28, indicating that its stock price is 72% less volatile than the broader market.

In the previous week, Pulmonx had 2 more articles in the media than Lucid Diagnostics. MarketBeat recorded 2 mentions for Pulmonx and 0 mentions for Lucid Diagnostics. Lucid Diagnostics' average media sentiment score of 0.00 equaled Pulmonx'saverage media sentiment score.

Company	Overall Sentiment
Lucid Diagnostics	Neutral
Pulmonx	Neutral

74.0% of Lucid Diagnostics shares are held by institutional investors. Comparatively, 91.0% of Pulmonx shares are held by institutional investors. 6.9% of Lucid Diagnostics shares are held by company insiders. Comparatively, 6.8% of Pulmonx shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Lucid Diagnostics currently has a consensus price target of $4.19, indicating a potential upside of 306.55%. Pulmonx has a consensus price target of $5.58, indicating a potential upside of 336.20%. Given Pulmonx's higher possible upside, analysts plainly believe Pulmonx is more favorable than Lucid Diagnostics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lucid Diagnostics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Pulmonx	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

Pulmonx has higher revenue and earnings than Lucid Diagnostics. Lucid Diagnostics is trading at a lower price-to-earnings ratio than Pulmonx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lucid Diagnostics	$5.13M	40.74	-$58.01M	-$0.47	N/A
Pulmonx	$90.50M	0.60	-$54M	-$1.30	N/A

Summary

Pulmonx beats Lucid Diagnostics on 8 of the 14 factors compared between the two stocks.

How does Pulmonx compare to RxSight?

RxSight (NASDAQ:RXST) and Pulmonx (NASDAQ:LUNG) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, institutional ownership, risk, earnings, analyst recommendations, dividends, media sentiment and profitability.

RxSight has higher revenue and earnings than Pulmonx. RxSight is trading at a lower price-to-earnings ratio than Pulmonx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
RxSight	$127.48M	1.70	-$38.94M	-$1.13	N/A
Pulmonx	$90.50M	0.60	-$54M	-$1.30	N/A

RxSight currently has a consensus price target of $9.44, suggesting a potential upside of 80.93%. Pulmonx has a consensus price target of $5.58, suggesting a potential upside of 336.20%. Given Pulmonx's stronger consensus rating and higher probable upside, analysts plainly believe Pulmonx is more favorable than RxSight.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
RxSight	3 Sell rating(s)	10 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.93
Pulmonx	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

RxSight has a net margin of -36.58% compared to Pulmonx's net margin of -60.09%. RxSight's return on equity of -17.01% beat Pulmonx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
RxSight	-36.58%	-17.01%	-15.12%
Pulmonx	-60.09%	-92.94%	-39.80%

78.8% of RxSight shares are held by institutional investors. Comparatively, 91.0% of Pulmonx shares are held by institutional investors. 10.1% of RxSight shares are held by company insiders. Comparatively, 6.8% of Pulmonx shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Pulmonx had 1 more articles in the media than RxSight. MarketBeat recorded 2 mentions for Pulmonx and 1 mentions for RxSight. RxSight's average media sentiment score of 0.00 equaled Pulmonx'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
RxSight	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Pulmonx	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

RxSight has a beta of 1.14, indicating that its stock price is 14% more volatile than the broader market. Comparatively, Pulmonx has a beta of 0.28, indicating that its stock price is 72% less volatile than the broader market.

Summary

RxSight beats Pulmonx on 9 of the 15 factors compared between the two stocks.

How does Pulmonx compare to Sanara MedTech?

Sanara MedTech (NASDAQ:SMTI) and Pulmonx (NASDAQ:LUNG) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, analyst recommendations, media sentiment, institutional ownership, earnings, dividends and profitability.

Sanara MedTech currently has a consensus price target of $34.00, indicating a potential upside of 56.32%. Pulmonx has a consensus price target of $5.58, indicating a potential upside of 336.20%. Given Pulmonx's higher possible upside, analysts plainly believe Pulmonx is more favorable than Sanara MedTech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sanara MedTech	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60
Pulmonx	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

Sanara MedTech has a net margin of -31.23% compared to Pulmonx's net margin of -60.09%. Sanara MedTech's return on equity of -3.19% beat Pulmonx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sanara MedTech	-31.23%	-3.19%	-0.56%
Pulmonx	-60.09%	-92.94%	-39.80%

In the previous week, Sanara MedTech and Sanara MedTech both had 2 articles in the media. Sanara MedTech's average media sentiment score of 1.78 beat Pulmonx's score of 0.00 indicating that Sanara MedTech is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sanara MedTech	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Pulmonx	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

8.1% of Sanara MedTech shares are held by institutional investors. Comparatively, 91.0% of Pulmonx shares are held by institutional investors. 42.0% of Sanara MedTech shares are held by company insiders. Comparatively, 6.8% of Pulmonx shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Sanara MedTech has higher revenue and earnings than Pulmonx. Sanara MedTech is trading at a lower price-to-earnings ratio than Pulmonx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sanara MedTech	$103.12M	1.93	-$37.56M	-$3.77	N/A
Pulmonx	$90.50M	0.60	-$54M	-$1.30	N/A

Sanara MedTech has a beta of 1.21, indicating that its stock price is 21% more volatile than the broader market. Comparatively, Pulmonx has a beta of 0.28, indicating that its stock price is 72% less volatile than the broader market.

Summary

Sanara MedTech beats Pulmonx on 11 of the 16 factors compared between the two stocks.

Get Pulmonx News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LUNG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LUNG vs. The Competition

Export

Metric	Pulmonx	MEDICAL INFO SYS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$53.64M	$1.54B	$6.44B	$12.30B
Dividend Yield	N/A	N/A	2.69%	5.83%
P/E Ratio	-0.98	77.66	24.66	23.99
Price / Sales	0.60	7.28	531.91	108.06
Price / Cash	N/A	23.50	44.82	54.51
Price / Book	0.98	5.16	10.81	6.50
Net Income	-$54M	-$54.76M	$3.56B	$336.88M
7 Day Performance	2.40%	-0.61%	0.93%	-0.16%
1 Month Performance	-17.42%	-3.64%	0.35%	0.76%
1 Year Performance	-52.42%	-4.16%	29.69%	28.49%

Pulmonx Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LUNG Pulmonx	1.7863 of 5 stars	$1.28 +0.8%	$5.58 +336.2%	-50.2%	$53.64M	$90.50M	N/A	250	News Coverage Gap Down
PDEX Pro-Dex	2.1189 of 5 stars	$63.72 +2.4%	$70.00 +9.9%	+51.6%	$198.59M	$66.59M	17.60	140
APYX Apyx Medical	2.7434 of 5 stars	$4.60 -1.9%	$6.50 +41.3%	+104.0%	$196.39M	$52.84M	N/A	270	Positive News
LUCD Lucid Diagnostics	4.0444 of 5 stars	$1.00 +4.1%	$4.19 +318.8%	-13.4%	$195.09M	$4.71M	N/A	70
RXST RxSight	2.5237 of 5 stars	$4.79 +1.7%	$9.44 +97.2%	-61.4%	$194.98M	$134.48M	N/A	220	News Coverage Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LUNG) was last updated on 6/24/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Pulmonx (LUNG) Competitors

LUNG vs. PDEX, APYX, LUCD, RXST, and SMTI

How does Pulmonx compare to Pro-Dex?

Summary

How does Pulmonx compare to Apyx Medical?

Summary

How does Pulmonx compare to Lucid Diagnostics?

Summary

How does Pulmonx compare to RxSight?

Summary

How does Pulmonx compare to Sanara MedTech?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LUNG vs. The Competition

Pulmonx Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Pulmonx (LUNG) Competitors

LUNG vs. PDEX, APYX, LUCD, RXST, and SMTI

How does Pulmonx compare to Pro-Dex?

Do insiders and institutionals believe in PDEX or LUNG?

Is PDEX or LUNG more profitable?

Which has more risk and volatility, PDEX or LUNG?

Does the media favor PDEX or LUNG?

Do analysts rate PDEX or LUNG?

Which has preferable valuation and earnings, PDEX or LUNG?

Summary

How does Pulmonx compare to Apyx Medical?

Is APYX or LUNG more profitable?

Do institutionals and insiders believe in APYX or LUNG?

Do analysts recommend APYX or LUNG?

Does the media prefer APYX or LUNG?

Which has more volatility & risk, APYX or LUNG?

Which has stronger valuation & earnings, APYX or LUNG?

Summary

How does Pulmonx compare to Lucid Diagnostics?

Is LUCD or LUNG more profitable?

Which has more risk and volatility, LUCD or LUNG?

Does the media prefer LUCD or LUNG?

Do institutionals and insiders hold more shares of LUCD or LUNG?

Do analysts rate LUCD or LUNG?

Which has better valuation & earnings, LUCD or LUNG?

Summary

How does Pulmonx compare to RxSight?

Which has better earnings & valuation, RXST or LUNG?

Do analysts prefer RXST or LUNG?

Is RXST or LUNG more profitable?

Do insiders & institutionals have more ownership in RXST or LUNG?

Does the media favor RXST or LUNG?

Which has more volatility and risk, RXST or LUNG?

Summary

How does Pulmonx compare to Sanara MedTech?

Do analysts recommend SMTI or LUNG?

Is SMTI or LUNG more profitable?

Does the media prefer SMTI or LUNG?

Do insiders and institutionals believe in SMTI or LUNG?

Which has higher valuation & earnings, SMTI or LUNG?

Which has more risk and volatility, SMTI or LUNG?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LUNG vs. The Competition

Pulmonx Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools